• A R Willan and D Y Lin.
• Department of Clinical Epidemiology and Biostatistics, McMaster University and Centre for Evaluation of Medicines, St Joseph's Hospital, 600-143 James Street South, Hamilton, ON, L8P 3A1, Canada. willana@mcmaster.ca
• Stat Med. 2001 Jun 15;20(11):1563-74.

AbstractThere are three approaches to health economic evaluation for comparing two therapies. These are (i) cost minimization, in which one assumes or observes no difference in effectiveness, (ii) incremental cost-effectiveness, and (iii) incremental net benefit. The latter can be expressed either in units of effectiveness or costs. When analysing data from a clinical trial, expressing incremental net benefit in units of cost allows the investigator to examine all three approaches in a single graph, complete with the corresponding statistical inferences. Furthermore, if costs and effectiveness are not censored, this can be achieved using common two-sample statistical procedures. The above will be illustrated using two examples, one with censoring and one without.Copyright 2001 John Wiley & Sons, Ltd.

27 keywords...

hide…